The short version of dihexa fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-16. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
However, there has been little in the way of direct comparisons between different types of beta blockers. In any case, the physiological symptoms of the fight-or-flight response (pounding heart, cold/clammy hands, increased respiration, sweating, etc.) are significantly reduced, thus enabling anxious individuals to concentrate on the task at hand. Although it is thought that beta blockers may act via peripheral mechanisms, there are also findings from preclinical research of central β-adrenergic receptors mediating anxiety. Musicians, public speakers, actors, models and adult performers, athletes, and professional dancers have been known to use beta blockers to avoid performance anxiety, stage fright, and tremor during both auditions and public performances. The application to stage fright was first recognized in The Lancet in 1976, and by 1987, a survey conducted by the International Conference of Symphony Orchestra Musicians, representing the 51 largest orchestras in the United States, revealed 27% of its musicians had used beta blockers and 70% obtained them from friends, not physicians. Beta blockers are inexpensive, said to be relatively safe, and on one hand, seem to improve musicians' performances on a technical level, while some, such as Barry Green, the author of "The Inner Game of Music" and Don Greene, a former Olympic diving coach who teaches Juilliard students to overcome their stage fright naturally, say the performances may be perceived as "soulless and inauthentic".
MR-2034, or Mr-2034, also known as (–)-MR-2033, is a selective κ-opioid receptor (KOR) agonist of the benzomorphan family. Unlike other benzomorphan KOR agonists like cyclazocine and alazocine, MR-2034 does not also act on sigma receptors. In addition to the KOR, it has affinity for the μ-opioid receptor (MOR), but does not activate this receptor. The drug produces dose-dependent hallucinogenic and dysphoric effects in humans, as well as other effects such as dizziness, anxiety, and sedation. These effects can be blocked by the non-selective opioid receptor antagonist naloxone. The preceding findings led to the conclusion that the hallucinogenic and dysphoric effects of benzomorphans are mediated by the KOR rather than by sigma receptors. MR-2034 was first described in the scientific literature by 1975 and its hallucinogenic effects in humans were described in 1986.
Airways, including hilar adenopathy or enlargement Breast shadows Bones, e.g. rib fractures and lytic bone lesions Cardiac silhouette, detecting cardiac enlargement Costophrenic angles, including pleural effusions Diaphragm, e.g. evidence of free air, indicative of perforation of an abdominal viscus Edges, e.g. apices for fibrosis, pneumothorax, pleural thickening or plaques Extrathoracic tissues Fields (lung parenchyma), being evidence of alveolar flooding Failure, e.g. alveolar air space disease with prominent vascularity with or without pleural effusions
Sources: en.wikipedia.org
==== 2017–2018 service disruptions and track improvements ==== Since the early 2010s, Amtrak had planned to fix the deteriorating rails and infrastructure around Penn Station, but due to the prioritization of other projects, applied only minimal fixes. In early 2017, this culminated in numerous power outages, derailments, and delays due to track maintenance delays. There were frequent service disruptions to train schedules caused by the deterioration of its tracks and their supporting infrastructure, as well as in those of the East River and North River tunnels that respectively connect the station to Long Island and New Jersey. A string of early 2017 service disruptions started on March 23, 2017, when an Acela train derailed, causing delays for the day. On April 3, a NJ Transit train derailed at a known problem site, where repairs had been deferred. This caused four days of reduced service along the Northeast Corridor for both Amtrak and NJ Transit, because the incident damaged the switch that connects Tracks 1–8 to the North River tunnels. This closure caused a cascading failure, delaying Amtrak and Long Island Rail Road trains on the unaffected tracks. On April 14, a New Jersey Transit train became stuck in the North River tunnels, causing the station to grow crowded with waiting passengers. After an Amtrak police officer used a Taser on a man who was acting disruptively, rumors of gunshots sparked a stampede that injured 16 people. Following the stampede, U.S. Senator Chuck Schumer called on Amtrak to centralize law enforcement response.
== Career == Townsend held various academic positions at the Medical University of South Carolina, starting as a Research Assistant Professor (2004) in the Department of Pharmaceutical Sciences. She was appointed as an associate professor in the Drug Discovery and Biomedical Sciences department in 2015 and has been serving as a Professor and acting department chair. In 2021, Townsend became the co-director of the Administrative Core for the Redox COBRE.
==== Economic impact on Denmark ==== By 2023, Novo Nordisk was the most valuable corporation in the European Union, worth more than US$500 billion, and accounted for almost all economic growth in Denmark. The large amounts of foreign currency earned by Novo Nordisk from Wegovy and Ozempic sales, when converted to Danish krone, have exerted upward pressure on the value of the krone, making it necessary for Danmarks Nationalbank to maintain lower interest rates than the European Central Bank. Poor clinical trial results published by Novo Nordisk in December 2024 contributed to a drop in the krone's value. Profits from Novo Nordisk result in increased Danish tax revenues and employment. Novo Nordisk added 3,500 jobs in Denmark in 2022, bringing the total in the country to 21,000 employees, out of 59,000 worldwide. As of February 2026, Novo Nordisk has a market capitalization of $220.42 billion.
== External links == Examination of Leonardo da Vinci's Madonna of the Yarnwinder using PIXE[link removed] Application of PIXE to the study of Renaissance style enameled gold jewelry (PDF) PDI-PIXE-MS: Particle Desorption Ionization Particle-Induced X-Ray Emission Mass Spectrometry (PDF) PIXEMS PNNL031209 – Pacific Northwest National Laboratory Presentation – "Particle Desorption Ionization Particle-Induced X-Ray Emission Mass Spectrometry" – PDI-PIXE-MS. (PDF) Sproch, N., Ashbaugh, M.D., Morse, D., Grant, P., McIntyre Jr., L.C., Antolak, A., Fernando, Q., "PD/PIXE-MS: Particle Desorption Particle Induced X-ray Emission Mass Spectrometry", Proceedings of the 49th ASMS Conference on Mass Spectrometry and Allied Topics; Chicago, Il, May 27 – May 31, 2001.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.